Kernal Bio

Kernal Bio, Inc., a Cambridge, Massachusetts based biotech company founded in 2019 by Yusuf Erkul, M.D., Cafer Ozdemir, PhD and Burak Yilmaz, is at the forefront of developing innovative mRNA therapies for cancer and severe diseases. Kernal Bio was established with a mission to revolutionize cancer treatment through onco-selective mRNA therapies, ensuring that these therapies are specifically activated in cancer cells to maximize efficacy and minimize side effects. The company aims to address the challenges of traditional cancer therapies, such as off-target effects and toxicity, by developing mRNA 2.0 therapies, which are designed to selectively translate in cancer cells, offering a novel approach to oncology.

Co-founders: Yusuf Erkul, Cafer Ozdemir, and Burak Yilmaz

‍